-
Mashup Score: 5Emerging Therapies for Chronic Graft-Versus-Host Disease - 3 day(s) ago
This segment of the virtual tumor board presentation focuses on the clinical development and use of emerging therapies, specifically Belumosudil, for the management of chronic graft-versus-host disease (cGvHD) following hematopoietic stem cell transplantation.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Updates on the iNTEGRATE and ROCKstar Trials - 7 day(s) ago
Yi-Bin Chen, MD, provides an overview of the iNTEGRATE and ROCKstar trials, underscoring their significance in the current treatment paradigm for graft versus host disease, particularly highlighting their ability to inhibit the fibrosis cascade, which offers substantial benefits for patient healing and recovery.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Cancer can be an isolating condition, so Meredith Cowden has made it her mission to ensure other patients are not alone. Meredith, a cancer survivor living with chronic graft versus host disease (cGVHD), responded to adversity by forming the Meredith A. Cowden Foundation with her family to support and advocate for fellow transplant patients. The key to Meredith’s success is her ability to advocate and form a successful alliance of advocacy groups that strengthens their ability to help and advocate for the cGVHD community. In this episode, Sanofi host Eric Racine and co-host Angie Bricco discuss with Meredith the keys to forming successful advocacy group alliances that encourage communication and collaboration to effectively help meet patient needs.
Categories: General Medicine News, PayerTweet-
Episode 3 of Patient Advocacy Voices is here. Listen in as Meredith Cowden from @cowdenfdn discusses #GVHD and the power of forging alliances and collaboration between patients and organizations to meet common goals with hosts Eric Racine and Angie Bricco. https://t.co/UkgnjlXMDl https://t.co/iLi3oXt8QK
-
-
Mashup Score: 0Setting Expectations + First-Line and Second-Line Treatment of Graft Versus Host Disease - 9 day(s) ago
A medical professional outlines the goals and challenges of communicating with his patient, emphasizing the importance of setting realistic expectations for halting disease progression and potentially achieving some degree of disease reversibility, while also exploring the roles of first-line and second-line therapies in the management of chronic graft versus host disease.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Patient Case: Pathology of Graft Versus Host Disease - 10 day(s) ago
Yi-Bin Chen, MD, presents a patient case, detailing the symptomology and pathology of graft versus host disease, such as dry eyes, dry mouth, and difficulty swallowing, while also addressing steroid dependence as an indication for initiating second-line therapy.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Axatilimab Trial Results - 11 day(s) ago
Evaluating the significance of the AGAVE-201 trial results for axatilimab in refractory chronic GvHD and key factors to consider when assessing the data.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Monitoring and Mitigating Adverse Events - 16 day(s) ago
Exploring general principles and practices for monitoring and mitigating adverse events in patients with chronic GvHD treated with systemic agents, and determining when dose modification or treatment discontinuation is warranted.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Safety Concerns with Ruxolitinib - 18 day(s) ago
Discussing the key safety issues observed with ruxolitinib treatment in the REACH-3 trial and evaluating the risk/benefit profile for patients with steroid-refractory chronic GvHD.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Ruxolitinib Improves Survival but Increases Infections in Acute GVHD - 1 month(s) ago
Chelsea Peterson, DO, discussed a real-world study investigating ruxolitinib in patients with steroid-refractory graft-vs-host disease.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Experts Discuss Emerging Therapies for Chronic Graft-Versus-Host Disease. #GVHD | @CatherineLeeMD @fredhutch @harvardmed @MassGeneralNews https://t.co/eS78u2XjQt